Corcept Therapeutics Incorporated (CORT)

Financial leverage ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Total assets	US$ in thousands	840,553	784,257	714,555	655,935	621,517	594,022	524,625	617,848	583,430	533,255	496,364	468,123	423,756	585,399	568,480	552,398	571,731	534,125	497,823	445,494
Total stockholders’ equity	US$ in thousands	679,589	638,835	596,243	547,864	506,705	461,679	421,614	529,584	501,842	473,364	442,326	407,811	375,806	540,229	522,675	510,802	523,338	489,680	453,698	409,489
Financial leverage ratio		1.24	1.23	1.20	1.20	1.23	1.29	1.24	1.17	1.16	1.13	1.12	1.15	1.13	1.08	1.09	1.08	1.09	1.09	1.10	1.09

December 31, 2024 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $840,553K ÷ $679,589K
= 1.24

The financial leverage ratio of Corcept Therapeutics Incorporated has shown fluctuations over the analyzed periods, ranging from 1.08 to 1.29. The ratio indicates the company's level of debt relative to its equity, with a higher ratio suggesting higher financial leverage. From March 31, 2020, to June 30, 2022, the ratio remained relatively stable between 1.08 and 1.15. However, there was an increase in the ratio from June 30, 2022, reaching a peak of 1.29 on September 30, 2023, implying a higher reliance on debt financing during that period. The ratio then decreased to 1.20 by June 30, 2024, indicating a reduction in financial leverage. Overall, the company experienced fluctuations in its financial leverage ratio, which could reflect changes in its capital structure and debt management strategies during the analyzed period.